Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Ingresos
109
108
113
3
40
20
Crecimiento de los Ingresos (YoY)
106%
-4%
3,667%
-93%
100%
33%
Costo de los ingresos
--
--
--
--
--
--
Utilidad bruta
--
--
--
--
--
--
Venta, General y Administración
70
59
51
50
46
42
Investigación y Desarrollo
174
159
130
115
121
130
Gastos de Operación
245
219
181
166
167
173
Otras Ingresos (Gastos) No Operativos
2
3
1
0
4
2
Ingreso antes de impuestos
-122
-97
-58
-161
-122
-150
Gasto por Impuesto a la Renta
0
0
0
0
0
0
Ingreso Neto
-122
-97
-58
-161
-122
-149
Crecimiento de la Utilidad Neta
-14%
67%
-64%
32%
-18%
-23%
Acciones en Circulación (Diluidas)
168
138
106
78.86
51.83
39.23
Cambio de Acciones (YoY)
26%
30%
34%
52%
32%
16%
EPS (Diluido)
-0.74
-0.7
-0.54
-2.05
-2.36
-3.82
Crecimiento de EPS
-31%
30%
-74%
-13%
-38%
-33%
Flujo de efectivo libre
-198
-151
-20
-129
-89
-117
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
--
--
--
--
--
--
Margen de operación
-124.77%
-101.85%
-60.17%
-5,400%
-317.5%
-765%
Margen de beneficio
-111.92%
-89.81%
-51.32%
-5,366.66%
-305%
-745%
Margen de flujo de caja libre
-181.65%
-139.81%
-17.69%
-4,300%
-222.5%
-585%
EBITDA
-133
-107
-63
-156
-120
-145
Margen de EBITDA
-122.01%
-99.07%
-55.75%
-5,200%
-300%
-725%
D&A para EBITDA
3
3
5
6
7
8
EBIT
-136
-110
-68
-162
-127
-153
Margen de EBIT
-124.77%
-101.85%
-60.17%
-5,400%
-317.5%
-765%
Tasa de Impuesto Efectiva
0%
0%
0%
0%
0%
0%
Estadísticas clave
Cierre Anterior
$13.27
Precio de apertura
$13.19
Rango del día
$12.51 - $13.23
Rango de 52 semanas
$5.28 - $21.73
Volumen
3.1M
Volumen promedio
6.9M
EPS (TTM)
-0.74
Rendimiento de dividendos
--
Cap. de mercado
$2.1B
¿Qué es WVE?
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 287 full-time employees The company went IPO on 2015-11-11. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).